Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis
MetadataShow full item record
AbstractThe World Health Organization recommended two new drugs, bedaquiline (BDQ) and delamanid (DLM), for the treatment of multidrug-resistant tuberculosis (MDR-TB) in 2013 and 2014, respectively. An estimated one third of patients with MDR-TB would benefit from the inclusion of these drugs in their treatment regimens.
- Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis.
- Authors: Furin J, Brigden G, Lessem E, Rich M, Vaughan L, Lynch S
- Issue date: 2016 Mar
- Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries.
- Authors: Guglielmetti L, Hewison C, Avaliani Z, Hughes J, Kiria N, Lomtadze N, Ndjeka N, Setkina S, Shabangu A, Sikhondze W, Skrahina A, Veziris N, Furin J
- Issue date: 2017 Feb 1
- Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
- Authors: Migliori GB, Pontali E, Sotgiu G, Centis R, D'Ambrosio L, Tiberi S, Tadolini M, Esposito S
- Issue date: 2017 Feb 7
- Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
- Authors: Wirth D, Dass R, Hettle R
- Issue date: 2017 Mar 8
- Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.
- Authors: Bonnet M, Bastard M, du Cros P, Khamraev A, Kimenye K, Khurkhumal S, Hayrapetyan A, Themba D, Telnov A, Sanchez-Padilla E, Hewison C, Varaine F
- Issue date: 2016 Feb